Company intelligence
NOUL Co., Ltd.
About NOUL Co., Ltd.
Noul Inc. has developed the next generation POC (Point-Of-Care) blood testing platform for resource-limited medical facilities, clinics, and local hospitals. Noul seeks to solve global challenges that threaten human life, to discover novel solutions, and to establish a new gold standard in POC blood testing. Noul’s solution aims to improve accessibility to proper health care by integrating innovations in biology, artificial intelligence, mobile technology, robotics, and software/hardware engineering. Noul has filed over 65 global patents, conducted more than seven field clinical trials, and has research partnerships with world-class global institutions. [Mission] We explore global challenges that threaten human health and life, discover novel potential solutions, and realize those possibilities. [Goal] 1. To contribute to eliminating malaria, tb, aids and other neglected diseases through innovative diagnostic platform. 2. To proactively increase healthcare accessibility through next-generation blood diagnostics platform.
Verified activity
Signals from NOUL Co., Ltd.
3 published signals
Presence & Recognition
NOUL Co., Ltd. will present an e-poster on miLab™ BCM at the ECP2026 European Congress of Pathology in Stockholm, Sweden from September 12 to 16, 2026.
Reported by NOUL Co., Ltd.
Customers & Market
NOUL Co., Ltd. AI-powered malaria diagnostic solution miLab™ MAL has been officially adopted by Benin's National Malaria Control Program following a public procurement tender by the Ministry of Health.
Reported by NOUL Co., Ltd.
Presence & Recognition
NOUL Co., Ltd. will be attending the 8th Korea-Africa Economic Cooperation Ministerial Conference at Grand Walkerhill Seoul, Seoul, Korea from September 8 to 11, 2026, under the theme “Harnessing AI and Digital Infrastructure for Africa’s Transformation,” showcasing the miLab™ and featuring David Lim as a speaker at the Ministerial Roundtable.
Reported by NOUL Co., Ltd.